

Candriam Equities L Europe Innovation

Market Overview

The long-anticipated start of the Federal Reserve's rate cutting cycle (by 50bp) finally arrived this September, along with a less hawkish tone from Japanese policymakers and new stimulus in China. All this helped to soothe investor concerns and support a strong rally in stocks into the end of the month.

This said, there are certainly a number of factors that are hampering investor's enthusiasm. Weaker macro data in the US and certainly in Europe, are slightly raising the (still low) probability of recession. Military conflicts in the Middle East and in Ukraine are far from over and weigh on investor's confidence. At the same time, one should not underestimate the uncertainty due to presidential elections in the US and difficult government formation in several European countries.

Regarding inflation in Europe, services price gains remains sticky, but there are hints of improvement. Price expectations from the EU survey also point to the GDP deflator slowing further. With inflation cooling and activity relatively muted, other western central banks also deemed it appropriate to cut rates.

Portfolio Highlights

In September, European equities closed the month broadly unchanged. After an initial market decline, market was reassured by the start of the Fed rate cutting cycle and new stimulus in China.

The fund outperformed its benchmark. Our key positive contributors included Carl Zeiss Meditec and Hexagon (both names helped by better sentiment in China) as well as Kingspan.

The key performance detractors were Tomra, Genmab and Nestle.

During the month, we slightly decreased exposure to Novonosis. And finally, we slightly increased Croda.

Fund Outlook

The environment should be more favourable to our portfolio given the ongoing rate-cutting cycle from central banks, which will put an end to the increase in long-term rates. Indeed, Quality/Growth companies will benefit from better valuation metrics and lower financing conditions. In addition, the supply-chain normalization should support B2B suppliers that suffered from a long destocking phase.

Our actual defensive sector allocation may be revised in the coming weeks, ahead of the US elections. A Trump victory with a clear Congress majority would lead to increased long-term rates (negative for Real Estate, positive for Banks). It would be also negative for some European sectors exposed to tariffs (like Automobiles). A clear Harris victory (min. 50 senators) would negatively weigh on Aerospace & Defence and eventually on some Pharmaceuticals. Equity markets may suffer from her fiscal policy (higher corporate taxes).

Concerning China, the last measures announced are a clear positive for the sentiment ("Chinese Put") but the economic trend will stay depressed for a while.

For 2025, in line with our soft-landing scenario of the global economy, we expect Quality/Growth stocks (and particularly innovative companies) to outperform.

This marketing communication is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.

Warning: Past performance of a given financial instrument or index or an investment service or strategy, or simulations of past performance, or forecasts of future performance does not predict future returns. Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change.

In respect to money market funds, please be aware that an investment in a fund is different from an investment in deposits and that the investment's principal is capable of fluctuation. The fund does not rely on external support for guaranteeing its liquidity or stabilizing its NAV per unit or share. The risk of loss of the principal is borne by the investor.

Candriam consistently recommends investors to consult via our website www.candriam.com the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value ("NAV") of the funds. Investor rights and complaints procedure, are accessible on Candriam's dedicated regulatory webpages <https://www.candriam.com/en/professional/legal-and-disclaimer-candriam/regulatory-information/>. This information is available either in English or in local languages for each country where the fund's marketing is approved. According to the applicable laws and regulations, Candriam may decide to terminate the arrangements made for the marketing of a relevant fund at any time.

Information on sustainability-related aspects: the information on sustainability-related aspects contained in this communication are available on Candriam webpage <https://www.candriam.com/en/professional/market-insights/sfdr/>. The decision to invest in the promoted product should take into account all the characteristics or objectives of the promoted product as described in its prospectus, or in the information documents which are to be disclosed to investors in accordance with the applicable law.

Notice to investors in Switzerland: The information provided herein does not constitute an offer of financial instruments in Switzerland pursuant to the Swiss Financial Services Act ("FinSA") and its implementing ordinance. This is solely an advertisement pursuant to FinSA and its implementing ordinance for financial instruments.

Swiss representative: CACEIS (Switzerland) SA, Route de Signy 35, CH-1260 Nyon. The legal documents as well as the latest annual and semi-annual financial reports, if any, of the investment funds may be obtained free of charge from the Swiss representative.

Swiss paying agent: CACEIS Bank, Paris, succursale de Nyon/Suisse, Route de Signy, 35, CH-1260 Nyon. Place of performance: Route de Signy 35, CH-1260 Nyon. Place of jurisdiction: Route de Signy 35, CH-1260 Nyon.

Specific information for investors in France: the appointed representative and paying agent in France is CACEIS Bank, Luxembourg Branch, sis 1-3, place Valhubert, 75013 Paris, France. The prospectus, the key investor information, the articles of association or as applicable the management rules as well as the annual and semi-annual reports, each in paper form, are made available free of charge at the representative and paying agent in France.

Specific information for investors in Spain: Candriam Sucursal en España has its registered office at C/ Pedro Teixeira, 8, Edif. Iberia Mart I, planta 4, 28020 Madrid and is registered with the Comisión Nacional del Mercado de Valores (CNMV) as an European Economic Area management company with a branch. CNMV: 233